- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 26.02. | Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies | ||
| 26.02. | Protagonist plans to pocket $400M from Takeda rather than split US rusfertide profits | ||
| 26.02. | Viatris to cut 10% of workforce in 3-year overhaul, discloses fire at India plant | ||
| 25.02. | As BridgeBio's Attruby launch accelerates, CEO shrugs off recent EU pricing pressure fears | ||
| 25.02. | Charles River sells manufacturing and discovery businesses to fulfill promised pivot | ||
| 25.02. | To reach consumers interested in GLP-1s, audio is 'dramatically underutilized': SiriusXM survey | ||
| 25.02. | Sanofi assists Boston's World Cup plans with play for local engagement | ||
| 25.02. | How Evinova is Integrating AI into Clinical Development to Bring Big Impact to Big Pharma | ||
| 25.02. | With Texas site, Novartis rounds out radiopharma production plans amid $23B US investment blitz | ||
| 24.02. | Novo to knock down Ozempic, Wegovy list prices next year, but self-pay channels unaffected | ||
| 24.02. | BioMarin pulls hemophilia gene therapy Roctavian, taking $240M hit after divestiture efforts flounder | ||
| 24.02. | AstraZeneca CEO pay hits $23.9M amid 'significant geopolitical uncertainty' in 2025 | ||
| 24.02. | Indivior picks Havas to lead US marketing efforts as DTC push ramps up | ||
| 24.02. | Amid obesity push, Pfizer strikes deal worth up to $495M to market Sciwind's approved GLP-1 in China | ||
| 24.02. | Novartis settles 18-month-old lawsuit from estate of Baltimore woman whose cells were extracted 75 years ago | ||
| 24.02. | Immedica overcomes prior FDA rebuke for ultrarare disease med to score new approval | ||
| 23.02. | AbbVie advances US expansion with $380M for 2 new North Chicago API plants | ||
| 23.02. | Roche halts development of Enspryng in Duchenne muscular dystrophy | ||
| 23.02. | Europe pumps brakes on US trade deal after Supreme Court decision, Trump tirade | ||
| 23.02. | Bayer sues J&J over 'deeply flawed' promotional claims touting Erleada over Nubeqa | ||
| 23.02. | Vanda, with FDA nod for Bysanti, gains 2nd new drug approval in as many months | ||
| 23.02. | CDMO Bora locks in 5-year, $250M production agreement with GSK | ||
| 23.02. | Girding against Keytruda cliff, Merck splits oncology into standalone business unit | ||
| 23.02. | Fortress sells FDA voucher for $205M after Zycubo approval last month | ||
| 20.02. | Catalent cuts staff by 96 in another round of layoffs in Maryland |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.